Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn’s Disease
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
A Phase 2b study to evaluate the efficacy and safety of brazikumab (MEDI2070) in participants with moderate to severe Crohn’s disease who have failed or are intolerant to anti-tumor necrosis factor-alpha (anti-TNFα) therapy.
创建时间：
2016-01-15
